全文获取类型
收费全文 | 267990篇 |
免费 | 39834篇 |
国内免费 | 2821篇 |
专业分类
耳鼻咽喉 | 6336篇 |
儿科学 | 8832篇 |
妇产科学 | 4418篇 |
基础医学 | 19329篇 |
口腔科学 | 3789篇 |
临床医学 | 38180篇 |
内科学 | 71681篇 |
皮肤病学 | 8867篇 |
神经病学 | 26264篇 |
特种医学 | 10009篇 |
外国民族医学 | 1篇 |
外科学 | 57512篇 |
综合类 | 1906篇 |
现状与发展 | 72篇 |
一般理论 | 156篇 |
预防医学 | 17474篇 |
眼科学 | 6584篇 |
药学 | 9565篇 |
1篇 | |
中国医学 | 284篇 |
肿瘤学 | 19385篇 |
出版年
2024年 | 624篇 |
2023年 | 5220篇 |
2022年 | 2174篇 |
2021年 | 5318篇 |
2020年 | 7273篇 |
2019年 | 4467篇 |
2018年 | 9938篇 |
2017年 | 9157篇 |
2016年 | 10496篇 |
2015年 | 10905篇 |
2014年 | 19054篇 |
2013年 | 20720篇 |
2012年 | 13715篇 |
2011年 | 14327篇 |
2010年 | 15005篇 |
2009年 | 18461篇 |
2008年 | 13580篇 |
2007年 | 12343篇 |
2006年 | 14359篇 |
2005年 | 11729篇 |
2004年 | 10559篇 |
2003年 | 8966篇 |
2002年 | 8802篇 |
2001年 | 4901篇 |
2000年 | 3858篇 |
1999年 | 4350篇 |
1998年 | 4982篇 |
1997年 | 4560篇 |
1996年 | 4225篇 |
1995年 | 4051篇 |
1994年 | 2686篇 |
1993年 | 2303篇 |
1992年 | 2028篇 |
1991年 | 1992篇 |
1990年 | 1591篇 |
1989年 | 1674篇 |
1988年 | 1520篇 |
1987年 | 1333篇 |
1986年 | 1297篇 |
1985年 | 1213篇 |
1984年 | 1108篇 |
1983年 | 1044篇 |
1982年 | 1196篇 |
1981年 | 1004篇 |
1980年 | 894篇 |
1979年 | 675篇 |
1978年 | 678篇 |
1977年 | 746篇 |
1976年 | 521篇 |
1975年 | 549篇 |
排序方式: 共有10000条查询结果,搜索用时 421 毫秒
71.
Objectives
Iatrogenic injury of the Profunda Femoris Artery (PFA) at time of hip fixation surgery can increase morbidity and mortality and prolong the hospital stay. This is an injury that tends to pass unnoticed as a cause of postoperative deterioration despite being frequently reported in the literature. Our study aims to describe the anatomy of the PFA in relation to the medial femoral cortex with specific emphasis on its orientation relative to the position of a sliding hip screw side plate construct. By doing so we are able to present clear guidance to orthopaedic surgeons on how to avoid iatrogenic PFA injury at the time of hip fracture fixation.Methods
Using Computed Tomography Angiographic (CTA) studies, the course of the PFA in relation to the medial femoral cortex was traced in 44 patients (28 males and 16 females) with mean age of 65.6 years. Coronal and axial CT sections were cross-linked to specify the position of the PFA at 1?cm intervals.Results
The course of the artery could be divided into three parts relative to a fixed reference point. Proximal and distal parts of the artery were in a safer position in comparison to the middle part of the artery that was found very close to the femoral cortex and along the coronal axis of the femur (mean angle 2.9° from the femoral coronal axis and 13.8?mm from the medial femoral cortex). Using the commercially available side plate constructs, this part of the artery corresponded to the distal part of the plate (third and fourth holes).Conclusion
Special attention needs to be practiced by the operating surgeon while drilling into the third and fourth holes of the side plate. 相似文献72.
73.
Emile Gogineni Zaker Rana Michael Wotman Jessie Karten Adam Riegel Mihaela Marrero Luis Maduro Dev Kamdar Douglas Frank Doru Paul Nagashree Seetharamu Maged Ghaly 《Journal of Geriatric Oncology》2021,12(1):122-127
PurposeManagement of head and neck cancers (HNC) in older adults is a common but challenging clinical scenario. We assess the impact of Stereotactic Body Radiation Therapy (SBRT) on survival utilizing the Geriatric-8 (G8) questionnaire.Materials and methods171 HNC patients, deemed medically unfit for definitive treatment, were treated with SBRT ± systemic therapy. G8 questionnaires were collected at baseline, at 4–6 weeks, and at 2–3 months post-treatment. Patients were stratified according to their baseline G8 score: <11 as ‘vulnerable’, 11–14 as ‘intermediate’, and >14 as ‘fit’. Overall survival (OS) was assessed through univariate Kaplan Meier analysis. Repeated measures ANOVA was used to determine if baseline characteristics affected G8 score changes.ResultsMedian follow-up was seventeen months. 60% of patients presented with recurrent HNC, 30% with untreated HNC primaries, and 10% with metastatic non-HNC primaries. Median age was 75 years. Median Charlson Comorbidity Index score was 2. 51% of patients were ‘vulnerable’, 37% were ‘intermediate’, and 12% were ‘fit' at baseline, with median survival of 13.2, 24.3, and 41.0 months, respectively (p = .004). Patients who saw a decrease in their follow-up G8 score (n = 69) had significantly lower survival than patients who had stable or increased follow-up G8 scores (n = 102), with median survival of 8.6 vs 36.0 months (p < .001).ConclusionThe G8 questionnaire may be a useful tool in upfront treatment decision-making to predict prognosis and prevent older patients from receiving inappropriate anti-cancer treatment. Decline in follow-up G8 scores may also predict worse survival and aid in goals of care following treatment. 相似文献
74.
75.
Tarandovskiy Ivan D. Rajabi Ali A. Karnaukhova Elena Buehler Paul W. 《Journal of thrombosis and thrombolysis》2019,48(1):81-87
Journal of Thrombosis and Thrombolysis - C1-inhibitor (C1INH) was shown to enhance thrombin generation (TG) in the presence of thrombomodulin (TM) by reducing production of activated protein C.... 相似文献
76.
77.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
78.
79.
80.